Kanghong Pharmaceutical announced that 13 major products sold by the company and its subsidiaries have been included in the National Essential Medicines List, 2026 Edition. Among them, Conbercept Ophthalmic Injection Prefilled Syringe, Shugan Jieyu Capsules, Eszopiclone Tablets, and Tofacitinib Citrate Extended-Release Tablets are the four newly added products. The new list takes effect on September 1, 2026. The inclusion will facilitate the promotion and use of the products in medical institutions at all levels, and is expected to have a positive impact on market expansion and long-term development. In the first quarter of 2026, Kanghong Pharmaceutical achieved revenue of 1.046 billion yuan and net profit attributable to the parent company of 307 million yuan.
Chengdu Kanghong Pharmaceuticals Group Co LtdFour products newly added to National Essential Medicines List, expected to boost market expansion and sales in medical institutions.